Statement: the primary clinical trial accepts participants diagnosed with histologically or cytologically confirmed invasive breast cancer at stage 2 or 3. the secondary clinical trial does not mandate any particular stage of cancer for eligibility.
Primary_evidence: Inclusion Criteria:   Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging   Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.   Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.   For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy.   Patients must have the presence of significant residual invasive disease on pathologic review following their preoperative chemotherapy.   LVEF > institutional limits of normal after preoperative chemotherapy, as assessed by ECHO or nuclear medicine gated study, within 30 days prior to initiating protocol-based treatment.   ECOG performance status 0-1 Exclusion Criteria:   Inadequate organ function, as measured by laboratory assessment after preoperative chemotherapy and within 14 days of beginning protocol-based treatment   Patients with metastatic disease are ineligible.   Known HIV infection   Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding   Uncontrolled intercurrent illness   Non-healing wounds or major surgical procedures (such as breast surgery) other than that for venous access device or diagnostic study are not permitted within 28 day prior to enrollment   History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab   Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months. Patients with clinically significant peripheral arterial disease should also be excluded   History of bleeding diathesis or coagulopathy   History of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)   Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer   Patients with large or rapidly accumulating pleural or abdominal effusions   Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR   Chronic therapy with full dose aspirin (< 325 mg/day) or standard non-steroidal anti-inflammatory agents is allowed   Patients may not receive other investigational agents while on study
Secondary_evidence: Inclusion Criteria:   For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com   Patients with metastatic or advanced solid tumors   Women with histologically or cytologically confirmed triple negative breast carcinoma   Participants with histologically or cytologically confirmed pancreatic adenocarcinoma   Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) Exclusion Criteria:   Active brain metastases or leptomeningeal metastases.   Any serious or uncontrolled medical disorder   Prior malignancy active within the previous 3 years   Other protocol defined inclusion/exclusion criteria could apply